Hepcidin and ferroportin: iron redistribution in host defense

A hormone controls iron export, not iron destruction

The hepcidin–ferroportin system regulates movement between iron pools. Ferroportin exports iron from cells, including intestinal absorptive cells and macrophages recycling aged erythrocytes. Hepcidin, produced principally by the liver, reduces that export. Plasma iron can consequently fall while iron remains inside cells. This is redistribution and restricted entry into the circulation, not chemical destruction or proof of increased iron excretion. A blood measurement therefore describes one part of the system rather than the whole-body inventory. ^{[1] [5]}

Nemeth and colleagues established a direct molecular connection in 2004: hepcidin bound ferroportin, promoted its internalization and degradation, and reduced cellular iron efflux. Billesbølle and colleagues later visualized hepcidin bound to ferroportin by cryo-electron microscopy. The peptide blocked the outward-facing transport pathway. Their structural complexes used cobalt as an iron mimic, accompanied by transport and binding experiments. These complementary studies distinguish regulation of a ferrous-iron, Fe(II), exporter from extracellular chelation by a soluble iron-binding protein. ^{[1] [6]}

This distinction matters when asking what an intervention has achieved. Increasing iron inside a macrophage does not tell us whether it entered ferritin storage, a labile pool, or a membrane-bound compartment. Conversely, restoring plasma iron does not establish that red-cell precursors incorporated it into hemoglobin. The system requires measurements of transfer and destination as well as concentration. Its homeostatic role can be established independently of any claim about an evolutionary antimicrobial purpose. ^{[6] [4]}

Follow recycled iron through ferritin, transferrin, and heme-handling pathways →

Inflammation and red-cell demand send competing signals

The inflammatory link was demonstrated across experimental scales. In Nemeth and colleagues’ IL-6 study, six healthy volunteers receiving the cytokine developed increased urinary hepcidin and decreased serum iron and transferrin saturation. Cell and mouse experiments supported the signaling mechanism. The human result establishes rapid hypoferremia—low circulating iron—without requiring a pre-existing deficiency. It was an acute physiological study, not a demonstration that a brief IL-6 exposure causes chronic anemia or that IL-6 explains every inflammatory iron response. ^[5]

Erythropoietic demand can push in the other direction. Kautz and colleagues identified erythroferrone as an erythroblast-derived signal that suppresses hepcidin. In mice lacking this signal, hepcidin suppression after blood loss and recovery from anemia were impaired. The contribution was to connect red-cell demand to iron release through a defined hormonal pathway. It does not imply that demand always overrides inflammation. The final hepcidin concentration reflects competing biological inputs, making a single value difficult to interpret without timing and context. ^[7]

Nor is every fall in ferroportin attributable to hepcidin. Willemetz and colleagues observed reduced ferroportin expression during Salmonella infection even in hepcidin-deficient mice, together with related changes in cultured macrophages. Thus inflammatory regulation can reach the exporter by another route. This is relevant to microbial exploitation: a host cell can retain iron when the circulating hormone is absent. The finding establishes a hepcidin-independent response, without by itself identifying one microbial molecule responsible for manipulating it. ^[8]

Extracellular protection depends on iron species and strain

Arezes and colleagues tested the defense hypothesis in mice exposed to the iron-responsive extracellular bacterium Vibrio vulnificus. Hepcidin deficiency increased susceptibility; lowering circulating iron with a hepcidin agonist improved outcomes. The comparison helped separate plasma iron availability from pre-existing liver iron stores. It provides causal support for an antimicrobial benefit of redistribution in that model. It does not establish that a hepcidin agonist treats human infection, nor that its benefit reflects direct peptide killing of bacteria. ^[2]

Stefanova and colleagues refined the target pool: non-transferrin-bound iron, or NTBI, supported selected infections in their mouse and plasma models. Protection differed even between Yersinia enterocolitica strains: the siderophilic O9 strain responded differently from O8. The study also found no comparable effect in its Staphylococcus aureus or Mycobacterium tuberculosis models. Access to alternative iron sources is a plausible escape route, but these comparisons do not reduce all strain differences to one acquisition system. The evidence supports selective protection, not a rule covering every extracellular organism. ^[9]

The evolutionary interpretation should remain proportionate. These studies demonstrate present-day host benefit from a physiological control system and make nutritional immunity a well-supported functional explanation in selected settings. They do not reconstruct the historical selective events that produced hepcidin. A homeostatic pathway can provide antimicrobial protection while also serving iron balance, and can impose costs when sustained beyond the period in which withholding is useful. ^{[2] [9]}

Intracellular infection is not one iron environment

Chlosta and colleagues found that greater ferroportin expression limited intracellular Salmonella multiplication in J774 macrophages and HeLa cells; hepcidin reversed the protective effect of ordinary ferroportin. Bacterial iron-response measurements supported deprivation as an explanation, while the authors acknowledged possible indirect effects. The important reversal is that retaining iron in a host cell can benefit a microbe living there. The study does not justify calling hepcidin harmful in every intracellular infection, especially given the negative tuberculosis result in the separate mouse study. ^{[3] [9]}

Lim and colleagues showed why even total macrophage iron is insufficient. In their Salmonella models, hepcidin increased cytosolic iron while reducing iron available inside the Salmonella-containing vacuole. Ferroportin associated with that vacuole supported local iron delivery and antimicrobial reactive oxygen chemistry. This interpretation differs from a simple nutrient-starvation explanation: iron may serve host chemistry as well as microbial nutrition. Reporter behavior and oxidant measurements support the model, but do not constitute a universal calibration of every intracellular iron pool. ^[4]

These results should remain a productive tension. Cell type, transporter location, host defense machinery, bacterial physiology, and sampling time can change what the same concentration means. A microbe may avoid plasma deprivation by occupying another niche, but the niche can also expose it to iron-dependent host defenses. Resolving which effect dominates requires compartment-sensitive evidence; averaging all intracellular iron into one number can conceal the mechanism being tested. ^{[3] [4]}

Compare redistribution with direct lactoferrin binding and receptor-mediated escape →

Anemia is a tradeoff with several causes

Restricted iron delivery can reduce the material available for erythropoiesis, but anemia of inflammation is not simply a high-hepcidin laboratory result. Gardenghi and colleagues separated hepcidin and IL-6 effects in mice given an inflammatory stimulus made from heat-killed bacteria. Iron restriction, suppressed red-cell production, and shortened erythrocyte survival all contributed. That design is informative about inflammation without ongoing bacterial replication. It also means that correcting one iron-routing defect need not reverse every cause of anemia. ^[10]

Human evidence reinforces the importance of time. In an exploratory analysis of a rheumatoid arthritis trial, Isaacs and colleagues found that IL-6 receptor blockade was associated with an early hepcidin decline and later hemoglobin improvement. Ferritin and iron-binding capacity also changed. The temporal pattern is consistent with improved iron availability contributing to recovery, but the treatment alters multiple inflammatory processes; the analysis did not isolate hepcidin as the sole mediator. Hemoglobin recovery can lag behind changes in inflammatory and iron-regulatory biomarkers. ^[11]

Use the iron profile to distinguish chemical form, concentration, and biological access →

Test whether iron release is enough for recovery

This experiment would not decide whether increasing or decreasing hepcidin benefits a patient with an active infection. It would identify which part of the anemia response remains after iron withholding ends, helping future studies choose informative outcomes and sampling times. The broader lesson is to follow the metal across boundaries: protection in plasma, iron chemistry within a cell, and iron delivery to developing erythrocytes can move in different directions.

Explore other host strategies for withholding, routing, and using metals →